CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 50 enrolled
Drug / intervention
Otezladrug
Likely dose
Otezla 30mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03587194
NCT03587194Phase 4Completed

A Single Center Study to Evaluate the Effectiveness and Safety of Add on Enstilar® in Patients Using OTEZLA® for Moderate to Severe Plaque Psoriasis

Psoriasis Treatment Center of Central New Jersey·interventional·Posted Jul 16, 2018·Updated Apr 16, 2024

In Brief

A Phase 4 clinical trial evaluating Otezla for Psoriasis. Completed, enrolled 50 participants across 1 site.

Detailed Summary

Add-on Enstilar to Otezla therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesUnited States
CollaboratorsCelgene Corporation

Timeline

Phase 4CompletedFinished
20192020202120222023202420252026
First PostedJul 16, 2018
Enrollment StartJul 23, 2018
Primary CompletionJul 1, 2019
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 8.0 years ago

Interventions

Otezladrug

Otezla 30mg BID